Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 12, 2017 - Issue
Submit an article Journal homepage
69
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease

Kyung Hoon Kim1 Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul
,
Hye Seon Kang2 Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Bucheon St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon
,
Ju Sang Kim3 Division of Pulmonary Medicine, Department of Internal Medicine, Incheon St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon
,
Hyoung Kyu Yoon4 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul
,
Sung Kyoung Kim5 Division of Pulmonary Medicine, Department of Internal Medicine, St Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of KoreaCorrespondence[email protected]
&
Chin Kook Rhee1 Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, SeoulCorrespondence[email protected]
Pages 3449-3456 | Published online: 04 Dec 2017

Figures & data

Table 1 Baseline characteristics of the patients who continued or discontinued roflumilast use

Figure 1 Process of patient recruitment.

Note: A total of 270 patients receiving new-onset roflumilast prescriptions between 2012 and 2015 were selected, and 16 dose-unknown patients, 93 patients treated with 250 μg of roflumilast, and 7 BMI-unknown patients were excluded.
Abbreviation: BMI, body mass index.
Figure 1 Process of patient recruitment.

Figure 2 Rates of roflumilast discontinuation by BMI group.

Notes: In the underweight and normal BMI groups, the rates of roflumilast discontinuation were 41.4% and 45.4%, respectively. On the other hand, in the overweight and obese BMI groups, the roflumilast discontinuation rates were 22.5% and 19.0%, respectively.
Abbreviation: BMI, body mass index.
Figure 2 Rates of roflumilast discontinuation by BMI group.

Table 2 Factors associated with roflumilast discontinuation (univariate analysis)

Table 3 Factors associated with roflumilast discontinuation (multi variate analysis)

Table 4 Types of adverse events in patients who continued or discontinued roflumilast use

Table 5 Comparison of patient characteristics by number of adverse events

Table 6 Factors associated with roflumilast adverse events (univariate analysis)

Figure 3 Rates of roflumilast adverse events by BMI group.

Notes: In the underweight and normal BMI groups, the roflumilast adverse events rates were 41.4% and 45.3%, respectively. On the other hand, in the overweight and obese BMI groups, the roflumilast adverse events rates were 27.5% and 14.3%, respectively.
Abbreviation: BMI, body mass index.
Figure 3 Rates of roflumilast adverse events by BMI group.

Table 7 Factors associated with roflumilast adverse events (multivariate analysis)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.